Genetic Disorders Clinical Trial
Official title:
Reproducibility of the GeneTrait™ CGH Microarray System DX Using Whole Blood Samples
The objective of this study is to validate the performance characteristics of the GeneTrait CGH Microarray System DX. Reproducibility among sites, lots, and operators will be evaluated.
n/a
Observational Model: Defined Population, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00705055 -
Face Anthropometric Pattern Recognition Technology for Computer Aided Diagnosis of Human Genetic Disorders.
|
N/A | |
| Completed |
NCT00851409 -
A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
|
Phase 2 | |
| Completed |
NCT00262301 -
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
|
Phase 3 | |
| Completed |
NCT00261053 -
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
|
Phase 2 | |
| Completed |
NCT01902901 -
Clinical Implementation of Carrier Status Using Next Generation Sequencing
|
N/A | |
| Completed |
NCT00578435 -
Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis
|
Phase 2 | |
| Recruiting |
NCT03911531 -
Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops
|
||
| Completed |
NCT01401257 -
Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
|
Phase 2 | |
| Completed |
NCT00262288 -
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
|
Phase 2/Phase 3 |